HK1215173A1 - 治療金黃色葡萄球菌相關疾病的方法 - Google Patents

治療金黃色葡萄球菌相關疾病的方法

Info

Publication number
HK1215173A1
HK1215173A1 HK16103165.5A HK16103165A HK1215173A1 HK 1215173 A1 HK1215173 A1 HK 1215173A1 HK 16103165 A HK16103165 A HK 16103165A HK 1215173 A1 HK1215173 A1 HK 1215173A1
Authority
HK
Hong Kong
Prior art keywords
aureus
treating
methods
associated diseases
diseases
Prior art date
Application number
HK16103165.5A
Other languages
English (en)
Inventor
Bret Sellman
Christine Tkaczyk
Melissa Hamilton
Lei Hua
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1215173A1 publication Critical patent/HK1215173A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HK16103165.5A 2012-11-06 2016-03-18 治療金黃色葡萄球菌相關疾病的方法 HK1215173A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Publications (1)

Publication Number Publication Date
HK1215173A1 true HK1215173A1 (zh) 2016-08-19

Family

ID=50685101

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103165.5A HK1215173A1 (zh) 2012-11-06 2016-03-18 治療金黃色葡萄球菌相關疾病的方法

Country Status (14)

Country Link
US (3) US9845348B2 (zh)
EP (1) EP2928490B1 (zh)
JP (2) JP6506172B2 (zh)
KR (3) KR20210083389A (zh)
CN (2) CN104780934A (zh)
AU (2) AU2013341421A1 (zh)
BR (1) BR112015010126B1 (zh)
CA (1) CA2890385C (zh)
ES (1) ES2912267T3 (zh)
HK (1) HK1215173A1 (zh)
MX (1) MX367082B (zh)
RU (1) RU2661406C2 (zh)
SG (2) SG11201503231YA (zh)
WO (1) WO2014074470A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2718320T3 (en) 2011-06-10 2018-03-26 Medimmune Ltd ANTI-PSEUDOMONAS-PSL BINDING MOLECULES AND APPLICATIONS THEREOF
ES2859323T3 (es) 2011-11-07 2021-10-01 Medimmune Ltd Terapias de combinación que usan moléculas de unión anti-Psl y PcrV de Pseudomonas
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
SG11201503232TA (en) * 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
US11059884B2 (en) 2018-10-09 2021-07-13 Medimmune, Llc Antibodies directed against Staphylococcus aureus leukotoxins
EP3864041A2 (en) 2018-10-09 2021-08-18 Medimmune, LLC Combinations of anti-staphylococcus aureus antibodies
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053235A1 (en) * 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2453881A2 (en) * 2009-07-16 2012-05-23 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
SG11201503232TA (en) 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
US20190002540A1 (en) 2019-01-03
US10457724B2 (en) 2019-10-29
JP2019142888A (ja) 2019-08-29
SG11201503231YA (en) 2015-05-28
RU2015121617A (ru) 2016-12-27
WO2014074470A1 (en) 2014-05-15
AU2018236849B2 (en) 2020-05-21
KR20150092738A (ko) 2015-08-13
JP6926138B2 (ja) 2021-08-25
CA2890385A1 (en) 2014-05-15
ES2912267T3 (es) 2022-05-25
CN112316135A (zh) 2021-02-05
EP2928490A1 (en) 2015-10-14
KR102272744B1 (ko) 2021-07-06
AU2018236849A1 (en) 2018-10-18
RU2661406C2 (ru) 2018-07-16
KR20210083389A (ko) 2021-07-06
CN104780934A (zh) 2015-07-15
MX367082B (es) 2019-08-05
US10759849B2 (en) 2020-09-01
MX2015005481A (es) 2016-01-14
BR112015010126A2 (zh) 2017-08-22
SG10201703677VA (en) 2017-06-29
EP2928490B1 (en) 2022-03-30
EP2928490A4 (en) 2016-11-02
US9845348B2 (en) 2017-12-19
BR112015010126B1 (pt) 2022-11-01
AU2013341421A1 (en) 2015-06-04
JP2015536951A (ja) 2015-12-24
KR20200102533A (ko) 2020-08-31
CA2890385C (en) 2022-07-12
US20160257733A1 (en) 2016-09-08
JP6506172B2 (ja) 2019-04-24
US20200109191A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
HK1204450A1 (zh) 治療腹腔疾病的方法
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2906208A4 (en) THERAPEUTIC TREATMENT
DK3292875T3 (en) Compositions and methods for treating diseases
EP2906295A4 (en) METHODS OF TREATING OCULAR DISEASES
HK1205254A1 (zh) 治療癌症的方法
HK1216504A1 (zh) 疾病的治療方法
GB2497886B (en) Hair treatment methods
IL238592A0 (en) Methods for treating liver diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
GB2500999B (en) Hair treatment methods
EP2911662A4 (en) METHOD OF TREATING A DISEASE
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201204645D0 (en) Treatment of disease
GB201221032D0 (en) Method of treatment
GB201207894D0 (en) Method of treatment
GB201205449D0 (en) Treatment process
GB201212604D0 (en) New treatment
GB201211135D0 (en) Treatment